Traws Pharma, Inc. (TRAW)
| Market Cap | 20.76M +210.9% |
| Revenue (ttm) | 2.73M +1,104.0% |
| Net Income | -13.91M |
| EPS | -1.52 |
| Shares Out | 15.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,482 |
| Open | 1.450 |
| Previous Close | 1.480 |
| Day's Range | 1.330 - 1.460 |
| 52-Week Range | 0.995 - 3.265 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 7.25 (+429.2%) |
| Earnings Date | May 15, 2026 |
About TRAW
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TRAW stock is "Buy." The 12-month stock price target is $7.25, which is an increase of 429.20% from the latest price.
News
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma announces antiviral program targeting Hantavirus, Ebola
Traws Pharma (TRAW) announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio. The investigational combination utilizes a unique “dual-strike” mecha...
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low ...
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma Quarterly report: Q1 2026
Traws Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
Traws Pharma Earnings release: Q1 2026
Traws Pharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Traws Pharma files to sell 35.9M shares of common stock for holders
17:05 EDT Traws Pharma (TRAW) files to sell 35.9M shares of common stock for holders
There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.
It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.
Traws Pharma Registration statement: Registration filing
Traws Pharma filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ta...
Traws Pharma Earnings Call Transcript: Q4 2025
Significant progress was made advancing a next-gen influenza antiviral, supported by $60M in new financing. Net income turned positive in 2025, and key clinical studies are planned in the UK, while US trials face an FDA clinical hold pending toxicology data resolution.
Traws Pharma Earnings release: Q4 2025
Traws Pharma released its Q4 2025 earnings on April 15, 2026, summarizing the period's financial results.
Traws Pharma Annual report: Q4 2025
Traws Pharma has published its Q4 2025 annual report on April 15, 2026.
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir
Traws Pharma (TRAW) announced the completion of the clinical analysis of its 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, v...
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; res...
Traws Pharma initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says the company offers an alternative to Cidara’s CD388.
Traws Pharma completes enrollment in Phase 2 study of ratutrelvir
Traws Pharma (TRAW) announced the completion of enrollment in its ongoing 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, vers...
Traws Pharma files tivoxavir marboxil IND application with U.S. FDA
Traws Pharma (TRAW) announced the filing of a U.S. IND application with the U.S. Food and Drug Administration, FDA, for tivoxavir marboxil, TXM, a CAP-dependent endonuclease inhibitor as a single…
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpil...
Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid
Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, demonstrated a differentiated clinical profile in a pre-specified...
Traws Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price target The company’s pipeline is led by two oral antivirals, ratutrelvir in…
Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year
Cash and cash equivalents: As of September 30, 2025, the Company had cash and cash equivalents of approximately $6.4 million, compared to approximately $21.3 million as of December 31, 2024.